Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03969706 · ClinicalTrials.gov registry record · Phase 2
Abemaciclib in Patients with Oligodendroglioma
A Phase 2 study of Oligodendroglioma, Adult, sponsored by Stephen Bagley, MD, MSCE.
- Active
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03969706: Active Phase 2 study of Oligodendroglioma, Adult, sponsored by Stephen Bagley, MD, MSCE.
NCT03969706 is a Phase 2 study of Oligodendroglioma, Adult that is active but no longer recruiting, run by Stephen Bagley, MD, MSCE. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03969706, a Phase 2 study of Oligodendroglioma, Adult, is active but no longer recruiting, sponsored by Stephen Bagley, MD, MSCE.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase II, single arm, open label study looking how well a drug called abemaciclib works in patients with recurrent oligodendroglioma
Primary Outcome
Assessed as a) Tumor progression (as measured by modified RANO criteria) or death due to disease or toxicity; OR b) alive without tumor progression
Conditions Studied
Interventions
- DRUG Abemaciclib 200 MG
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-05-15 |
| Est. Completion | 2027-05-15 |
| Phase | Phase 2 |
What the registry record for NCT03969706 still lists
NCT03969706 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Oligodendroglioma, Adult appearing as the primary indexed condition, and to 1 intervention - of which Abemaciclib 200 MG is the first listed.
NCT03969706 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03969706 about?
NCT03969706 is a clinical study titled "Abemaciclib in Patients with Oligodendroglioma". This is a phase II, single arm, open label study looking how well a drug called abemaciclib works in patients with recurrent oligodendroglioma
What is the current status of trial NCT03969706?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2019-05-15. Estimated completion is 2027-05-15.
What conditions does trial NCT03969706 study?
This clinical trial studies the following conditions: Oligodendroglioma, Adult.
What interventions are being tested in trial NCT03969706?
The interventions under investigation include: Abemaciclib 200 MG (DRUG).
Who is sponsoring clinical trial NCT03969706?
This trial is sponsored by Stephen Bagley, MD, MSCE, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03969706 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oligodendroglioma, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03969706's enrollment target sits among peer trials
10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI